IGF2R and cancer: This is an important observation, which means that the radiolabeled IF3 antibody will be binding in vivo only to the cancer cells that express IGF2R on their surface [4,5,6,7], while intracellular expression of IGF2R in normal tissue will remain invisible to the antibody, thus avoiding toxicity to normal tissues.